The Brazilian results suggest CoronaVac is far less effective than vaccines developed by Pfizer-BioNTech and Moderna, which have an efficacy rate of about 95%. The Sinovac vaccine has a lower efficacy rate than its domestic Chinese competitor, developed by the state-owned Sinopharm, which it says has a 79.34% efficacy. Under reviewThe Sinovac and Sinopharm vaccines have been regarded as potentially affordable and easily distributed vaccine candidates. Different efficacy ratesPart of the confusion over Sinovac's vaccine has been around different efficacy rates and the data made available. Turkey, which approved the Sinovac vaccine for emergency use on Wednesday, reported an efficacy of 91.25%, while Indonesia reported 65.3%.

Source: CNN January 18, 2021 02:53 UTC